Interventions of Interest

For questions please contact [email protected].

  • Comirnaty® (Covid-19 Vaccine, mRNA; Pfizer, BioNTech)
  • Spikevax® (Covid-19 Vaccine, mRNA; Moderna)
  • mNexspike® (Covid-19 Vaccine, mRNA; Moderna)
  • Nuvaxovid® (Covid-19 Vaccine, Adjuvanted; Sanofi)

Final Documents

Final Policy RecommendationsDownload
Final Evidence Report and Meeting SummaryDownload
Report-at-a-GlanceDownload
Draft Evidence ReportDownload
Response to Public CommentsDownload

ICER’s President and CEO Sarah K. Emond, MPP:

“The current confusion in the US around vaccine policy is challenging for both health care professionals and the American public. Policymakers, especially public health leaders, need reliable and unbiased assessments of how well therapies work for patients. For 20 years, ICER has delivered that through our evidence-based analyses and public meetings. This public meeting highlighted what we know about the current evidence on Covid-19 vaccines, and where there are opportunities to gain an even better understanding of how these vaccinations impact different subpopulations. Ultimately, ICER’s transparent and public process sheds light on the broader context that policymakers should consider when making recommendations about Covid-19 vaccines.”